Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBNX Beta Bionics	$13.52 -4.4%	$15.43	$8.89 ▼ $24.50	$586.18M	N/A	471,013 shs	121,291 shs
ENOV Enovis	$33.65 +0.6%	$32.99	$28.83 ▼ $49.83	$1.92B	1.7	890,833 shs	775,291 shs
NVCR NovoCure	$17.71 -1.0%	$17.70	$14.17 ▼ $34.13	$1.97B	0.72	1.13 million shs	534,101 shs
WRBY Warby Parker	$22.25 +1.3%	$19.96	$12.46 ▼ $28.68	$2.32B	2.09	1.98 million shs	564,025 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBNX Beta Bionics	0.00%	-10.29%	-30.84%	+36.43%	+1,351,999,900.00%
ENOV Enovis	0.00%	+5.89%	+6.51%	+3.47%	-24.25%
NVCR NovoCure	0.00%	-1.64%	+7.63%	+7.37%	+4.95%
WRBY Warby Parker	0.00%	+1.64%	+5.00%	+40.89%	+37.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBNX Beta Bionics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ENOV Enovis	3.5842 of 5 stars	3.4	3.0	0.0	0.0	3.2	1.7	1.9
NVCR NovoCure	3.6096 of 5 stars	3.3	1.0	0.0	4.5	2.0	1.7	0.0
WRBY Warby Parker	2.1868 of 5 stars	2.3	3.0	0.0	0.0	2.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBNX Beta Bionics	2.75	Moderate Buy	$23.44	73.41% Upside
ENOV Enovis	2.80	Moderate Buy	$58.00	72.36% Upside
NVCR NovoCure	2.67	Moderate Buy	$32.83	85.45% Upside
WRBY Warby Parker	2.61	Moderate Buy	$22.88	2.81% Upside

Current Analyst Ratings Breakdown

Latest BBNX, WRBY, NVCR, and ENOV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	NVCR NovoCure	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$34.00
6/16/2025	BBNX Beta Bionics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00
6/12/2025	BBNX Beta Bionics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$30.00
5/30/2025	BBNX Beta Bionics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$16.00
5/30/2025	BBNX Beta Bionics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$20.00
5/29/2025	WRBY Warby Parker	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00 ➝ $25.00
5/22/2025	WRBY Warby Parker	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$18.00 ➝ $21.00
5/21/2025	WRBY Warby Parker	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/21/2025	WRBY Warby Parker	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/21/2025	WRBY Warby Parker	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$17.00 ➝ $22.00
5/21/2025	WRBY Warby Parker	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$18.00 ➝ $21.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBNX Beta Bionics	$65.12M	9.00	N/A	N/A	($5.72) per share	-2.36
ENOV Enovis	$2.11B	0.91	$19.23 per share	1.75	$45.10 per share	0.75
NVCR NovoCure	$605.22M	3.26	N/A	N/A	$3.33 per share	5.32
WRBY Warby Parker	$771.32M	3.01	$0.34 per share	65.51	$3.35 per share	6.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBNX Beta Bionics	-$54.76M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ENOV Enovis	-$825.49M	-$13.95	N/A	10.55	N/A	-37.65%	5.99%	3.44%	8/6/2025 (Estimated)
NVCR NovoCure	-$168.63M	-$1.51	N/A	N/A	N/A	-26.41%	-45.46%	-13.34%	7/24/2025 (Estimated)
WRBY Warby Parker	-$20.39M	-$0.12	N/A	222.50	N/A	-1.79%	-2.48%	-1.29%	8/6/2025 (Estimated)

Latest BBNX, WRBY, NVCR, and ENOV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/24/2025	Q2 2025	NVCR NovoCure	-$0.40	N/A	N/A	N/A	$153.87 million	N/A
5/8/2025	Q1 2025	ENOV Enovis	$0.74	$0.81	+$0.07	-$0.98	$558.80 million	$558.83 million
5/6/2025	Q1 2025	BBNX Beta Bionics	-$0.51	-$0.52	-$0.01	-$0.93	N/A	N/A
4/24/2025	Q1 2025	NVCR NovoCure	-$0.47	-$0.31	+$0.16	-$0.31	$147.57 million	$154.99 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBNX Beta Bionics	N/A	N/A	N/A	N/A	N/A
ENOV Enovis	N/A	N/A	N/A	N/A	N/A
NVCR NovoCure	N/A	N/A	N/A	N/A	N/A
WRBY Warby Parker	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBNX Beta Bionics	N/A	15.88	14.93
ENOV Enovis	0.52	2.55	1.32
NVCR NovoCure	0.27	1.47	1.41
WRBY Warby Parker	N/A	2.70	2.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBNX Beta Bionics	N/A
ENOV Enovis	98.45%
NVCR NovoCure	84.61%
WRBY Warby Parker	93.24%

Insider Ownership

Company	Insider Ownership
BBNX Beta Bionics	N/A
ENOV Enovis	2.70%
NVCR NovoCure	5.52%
WRBY Warby Parker	18.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBNX Beta Bionics	294	43.36 million	N/A	N/A
ENOV Enovis	7,367	57.12 million	55.58 million	Optionable
NVCR NovoCure	1,488	111.49 million	105.33 million	Optionable
WRBY Warby Parker	3,780	104.50 million	85.44 million	Optionable

BBNX, WRBY, NVCR, and ENOV Headlines

Recent News About These Companies

Warby Parker Inc. (NYSE:WRBY) Receives Consensus Rating of "Moderate Buy" from Brokerages

July 6 at 3:09 AM | americanbankingnews.com

Warby Parker Inc. (NYSE:WRBY) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 6 at 3:07 AM | marketbeat.com

11,751 Shares in Warby Parker Inc. (NYSE:WRBY) Acquired by Diversified Trust Co

July 2, 2025 | marketbeat.com

What Makes Warby Parker (WRBY) an Attractive Investment?

June 30, 2025 | finance.yahoo.com

Bessemer Group Inc. Has $1.17 Million Stock Position in Warby Parker Inc. (NYSE:WRBY)

June 30, 2025 | marketbeat.com

WRBY - Warby Parker Inc Ordinary Shares - Class A Chart - Morningstar

June 28, 2025 | morningstar.comM

The 5 Most Interesting Analyst Questions From Warby Parker’s Q1 Earnings Call

June 27, 2025 | msn.com

Warby Parker (NYSE:WRBY) Stock Price Down 3.7% - Here's What Happened

June 26, 2025 | marketbeat.com

SG Americas Securities LLC Buys Shares of 33,023 Warby Parker Inc. (NYSE:WRBY)

June 22, 2025 | marketbeat.com

Warby Parker (WRBY): Buy, Sell, or Hold Post Q1 Earnings?

June 20, 2025 | msn.com

Riverwater Partners LLC Invests $460,000 in Warby Parker Inc. (NYSE:WRBY)

June 20, 2025 | marketbeat.com

Vaughan Nelson Investment Management L.P. Trims Stake in Warby Parker Inc. (NYSE:WRBY)

June 15, 2025 | marketbeat.com

Tech Giants Partner With Retailers As Smart Glasses Battle Heats Up

June 12, 2025 | forbes.com

Warby Parker eyes space at trendy Raleigh shopping center

June 11, 2025 | bizjournals.com

Warby Parker Inc. (NYSE:WRBY) Given Consensus Rating of "Moderate Buy" by Brokerages

June 11, 2025 | marketbeat.com

WRBY Q1 Earnings Call: Management Details Tariff Mitigation, Store Expansion, and Pricing Actions

June 10, 2025 | msn.com

NBC Securities Inc. Buys 11,574 Shares of Warby Parker Inc. (NYSE:WRBY)

June 9, 2025 | marketbeat.com

Ameriprise Financial Inc. Acquires New Shares in Warby Parker Inc. (NYSE:WRBY)

June 6, 2025 | marketbeat.com

Warby Parker Co-CEO: Google AI Glasses Coming After 2025

June 4, 2025 | pymnts.com

Warby Parker Announces Participation in the Baird Global Consumer, Technology & Services Conference

June 2, 2025 | finance.yahoo.com

June 2, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX, WRBY, NVCR, and ENOV Company Descriptions

Beta Bionics NASDAQ:BBNX

$13.52 -0.62 (-4.38%)

As of 07/3/2025 01:00 PM Eastern

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Enovis NYSE:ENOV

$33.65 +0.19 (+0.57%)

Closing price 07/3/2025 03:30 PM Eastern

Extended Trading

$33.66 +0.02 (+0.04%)

As of 07/3/2025 04:20 PM Eastern

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

NovoCure NASDAQ:NVCR

$17.70 -0.18 (-0.98%)

As of 07/3/2025 03:48 PM Eastern

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Warby Parker NYSE:WRBY

$22.25 +0.29 (+1.32%)

As of 07/3/2025 03:58 PM Eastern

Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time